XML 36 R24.htm IDEA: XBRL DOCUMENT v3.5.0.2
Fair Value Measurements (Cont Liab and Debt) (Details) - USD ($)
Jun. 23, 2014
Jun. 30, 2016
Apr. 30, 2014
8.00% Convertible Senior Notes Due 2019      
Additional fair value disclosures      
Aggregate principal amount $ 47,000,000    
Interest rate (as a percent) 8.00% 8.00%  
Debt outstanding   $ 43,750,000  
Period from conversion date considered for interest make-whole payment 3 years    
Shape Pharmaceuticals      
Additional fair value disclosures      
Percentage of share capital acquired     100.00%
Low end of range of undiscounted amounts     $ 0
High end of range of undiscounted amounts     $ 64,500,000